Stay updated with breaking news from Swati jalgaonkar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 News provided by Share this article Share this article SAN CARLOS, Calif., April 9, 2021 /PRNewswire/ Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021. Details are as follows: Title of Presentation : APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression (Abstract ID LB175) ....